MétaCan
Menu
Back to cohort
Record W4410463909 · doi:10.1016/j.esmoop.2025.104766

212P Cost-effectiveness analysis of ribociclib plus endocrine therapy (ET) versus ET alone in the adjuvant treatment of stage II and III pre and postmenopausal women with HR+/HER2− early breast cancer (EBC): A Canadian payer perspective

2025· article· en· W4410463909 on OpenAlexaffabout
Christine Brezden‐Masley, Dina Sameh Soliman, Sandeep Sehdev, K. El Ouagari, Andriy Danyliv, Daniel Stellato

Bibliographic record

VenueESMO Open · 2025
Typearticle
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsOttawa Regional Cancer FoundationNovartis (Canada)Mount Sinai Hospital
FundersDaiichi Sankyo EuropeIpsenEisaiPfizerMinistero della SaluteIncyteTeva Pharmaceutical IndustriesGilead SciencesAmgenAssociazione Italiana per la Ricerca sul CancroLes Laboratories Pierre FabreAstraZenecaEli Lilly and Company
KeywordsMedicineStage (stratigraphy)OncologyInternal medicineGynecologyPostmenopausal womenAdjuvantBreast cancerCancerBiology

Abstract

fetched live from OpenAlex

Objective: To evaluate the cost-effectiveness of ribociclib plus ET vs ET alone in the adjuvant treatment of stage II and II pre and postmenopausal women with HR+/HER2− EBC from a Canadian public payer perspective.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.242
Threshold uncertainty score0.487

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.009
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.004
Bibliometrics0.0010.002
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0080.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.370
Teacher spread0.346 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueESMO OpenSame topicAdvanced Breast Cancer TherapiesFrench-language works237,207